Compare RYAN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | GRFS |
|---|---|---|
| Founded | 2010 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.8B |
| IPO Year | 2021 | N/A |
| Metric | RYAN | GRFS |
|---|---|---|
| Price | $37.25 | $8.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 2 |
| Target Price | ★ $56.50 | $10.15 |
| AVG Volume (30 Days) | ★ 2.9M | 632.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | 1.31% | ★ 1.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | N/A |
| Revenue This Year | $18.15 | $5.33 |
| Revenue Next Year | $13.74 | $6.50 |
| P/E Ratio | $86.72 | ★ $18.67 |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $37.29 | $6.19 |
| 52 Week High | $77.00 | $11.14 |
| Indicator | RYAN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 30.76 | 33.82 |
| Support Level | N/A | $8.25 |
| Resistance Level | $59.01 | $9.11 |
| Average True Range (ATR) | 1.55 | 0.30 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 10.61 | 1.21 |
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.